Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05820672 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

Study acronym: SkybriGHt
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv8
  2. Study sites: 24 to 27v7
  3. Re-verified, no change to tracked fieldsv6
  4. Study sites: 25 to 24v5
  5. Study sites: 1 to 25v4
  6. 2 versions Re-verified since Nov 3, 2023, no change to tracked fieldsv2-v3
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care
Trial Details
NCT Number NCT05820672
Lead Sponsor Ascendis Pharma Endocrinology Division A/S
Conditions
(from sponsor)		 Growth Hormone Deficiency
Related terms Dwarfism, Pituitary
Enrollment 900 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov